Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene Autoleucel in Active, Refractory SLE or LN
NCT06581198Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2024
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 26
01
Overview
Phase 2, open-label, single-arm trial of rapcabtagene autoleucel in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Novartis. Primary endpoint: Evaluate the efficacy of rapcabtagene autoleucel at 52 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06581198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581198.